Clinical Trial Update: Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects [Phase 2]

View source ↗

Summary

This Phase 2 trial compared the antisecretory effect of a single 20 mg dose of rabeprazole versus 20 mg omeprazole in obese adults with gastroesophageal reflux …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Omeprazole (Omeprazole)
• Rabeprazole (rabeprazole)

Snippet

Sponsor: Nantes University Hospital | Conditions: Gastroesophageal Reflux | Phase 2 | Status: COMPLETED